Novabay Pharmaceuticals Inc (NBY) Stocks Reach New Highs at $0.15 During Trading Session

After finishing at $0.14 in the prior trading day, Novabay Pharmaceuticals Inc (AMEX: NBY) closed at $0.15, up 8.10%. In other words, the price has increased by $+0.0115 from its previous closing price. On the day, 3554631 shares were traded.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Ratios:

Our goal is to gain a better understanding of NBY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 0.43 whereas as Long-Term Debt/Eq ratio is at 0.18.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on September 18, 2019, initiated with a Buy rating and assigned the stock a target price of $1.10.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBY now has a Market Capitalization of 1.00M and an Enterprise Value of 2.51M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.07 while its Price-to-Book (P/B) ratio in mrq is 0.20. Its current Enterprise Value per Revenue stands at 0.17 whereas that against EBITDA is -0.38.

Stock Price History:

Over the past 52 weeks, NBY has reached a high of $2.60, while it has fallen to a 52-week low of $0.12. The 50-Day Moving Average of the stock is 0.2080, while the 200-Day Moving Average is calculated to be 0.5120.

Shares Statistics:

The stock has traded on average 1.40 shares per day over the past 3-months and 9.58M shares per day over the last 10 days, according to various share statistics. A total of 6.53M shares are outstanding, with a floating share count of 6.37M. Insiders hold about 2.44% of the company’s shares, while institutions hold 4.41% stake in the company. Shares short for NBY as of Jan 31, 2024 were 576.56k with a Short Ratio of 0.23, compared to 32.63k on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.83% and a Short% of Float of 8.84%.

Earnings Estimates

Its stock is currently analyzed by 2 different market analysts. On average, analysts expect EPS of -$0.3 for the current quarter, with a high estimate of -$0.3 and a low estimate of -$0.3, while EPS last year was -$0.78. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.2 and low estimates of -$0.23.

Analysts are recommending an EPS of between -$2.31 and -$2.54 for the fiscal current year, implying an average EPS of -$2.43. EPS for the following year is -$0.64, with 2 analysts recommending between -$0.55 and -$0.73.

Revenue Estimates

2 analysts predict $3.61M in revenue for the current quarter. It ranges from a high estimate of $3.83M to a low estimate of $3.4M. As of the current estimate, Novabay Pharmaceuticals Inc’s year-ago sales were $3.64M, an estimated decrease of -0.90% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $3.87M, an increase of 20.90% over than the figure of -$0.90% in the same quarter last year. There is a high estimate of $4M for the next quarter, whereas the lowest estimate is $3.75M.

A total of 2 analysts have provided revenue estimates for NBY’s current fiscal year. The highest revenue estimate was $14.86M, while the lowest revenue estimate was $14.4M, resulting in an average revenue estimate of $14.63M. In the same quarter a year ago, actual revenue was $14.4M, up 1.60% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $16.3M in the next fiscal year. The high estimate is $16.59M and the low estimate is $16M. The average revenue growth estimate for next year is up 11.40% from the average revenue estimate for this year.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular